Ovid Therapeutics Inc (OVID) Expected to Post Earnings of -$0.57 Per Share  Alanna Baker | Aug 17th, 2018
Brokerages expect that Ovid Therapeutics Inc (NASDAQ:OVID) will report earnings per share of ($0.57) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ovid Therapeutics' earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.59). Ovid Therapeutics reported earnings per share of ($0.38) during the same quarter last year, which suggests a negative year-over-year growth rate of 50%. The company is expected to announce its next quarterly earnings results on Thursday, November 8th.
On average, analysts expect that Ovid Therapeutics will report full-year earnings of ($2.26) per share for the current fiscal year, with EPS estimates ranging from ($2.36) to ($2.15). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.54) per share, with EPS estimates ranging from ($2.79) to ($2.25). Zacks Investment Research's EPS averages are an average based on a survey of research analysts that cover Ovid Therapeutics. Get Ovid Therapeutics alerts:
Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.07.
A number of equities analysts recently commented on OVID shares. Piper Jaffray Companies assumed coverage on Ovid Therapeutics in a report on Sunday, May 20th. They issued a "buy" rating and a $20.00 price objective on the stock. LADENBURG THALM/SH SH assumed coverage on Ovid Therapeutics in a research report on Friday, April 20th. They set a "buy" rating and a $27.00 target price for the company. Zacks Investment Research cut Ovid Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 10th. BidaskClub raised Ovid Therapeutics from a "hold" rating to a "buy" rating in a research report on Sunday, July 15th. Finally, ValuEngine raised Ovid Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company's stock. The stock presently has an average rating of "Hold" and an average price target of $19.33.
NASDAQ:OVID opened at $6.57 on Tuesday. Ovid Therapeutics has a 52 week low of $5.59 and a 52 week high of $12.44. The company has a market capitalization of $151.73 million, a P/E ratio of -1.96 and a beta of 2.05.
In related news, Director Douglas E. Williams bought 5,000 shares of the firm's stock in a transaction on Tuesday, August 14th. The stock was purchased at an average price of $6.49 per share, with a total value of $32,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . 43.90% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in OVID. Schwab Charles Investment Management Inc. boosted its position in Ovid Therapeutics by 67.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 34,295 shares of the company's stock worth $243,000 after purchasing an additional 13,785 shares during the period. Northern Trust Corp boosted its position in Ovid Therapeutics by 81.7% during the first quarter. Northern Trust Corp now owns 118,430 shares of the company's stock worth $837,000 after purchasing an additional 53,264 shares during the period. BlackRock Inc. boosted its position in Ovid Therapeutics by 27.8% during the first quarter. BlackRock Inc. now owns 1,358,459 shares of the company's stock worth $9,606,000 after purchasing an additional 295,247 shares during the period. Spark Investment Management LLC boosted its position in Ovid Therapeutics by 83.3% during the first quarter. Spark Investment Management LLC now owns 19,800 shares of the company's stock worth $139,000 after purchasing an additional 9,000 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Ovid Therapeutics by 482.8% during the first quarter. JPMorgan Chase & Co. now owns 33,006 shares of the company's stock worth $233,000 after purchasing an additional 27,343 shares during the period. 27.62% of the stock is owned by hedge funds and other institutional investors.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Ovid Therapeutics Ovid Therapeutic